Century Therapeutics (IPSC) Non-Current Assets (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Non-Current Assets data on file, last reported at $187.5 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 28.45% year-over-year to $187.5 million in Q1 2026; TTM through Mar 2026 was $522.0 million, a 25.51% decrease from a year earlier, with the FY2025 full-year figure at $102.9 million, down 35.33% from the prior year.
• Non-Current Assets for Q1 2026 stood at $187.5 million, up from $102.9 million in the prior quarter.
• Over the last five years, Non-Current Assets for IPSC reached as high as $255.9 million in Q2 2023 and fell as low as $102.9 million in Q4 2025.
• Historically, Non-Current Assets has averaged $169.8 million across 5 years, with a median of $166.8 million in 2022.
• Across the five-year window, Non-Current Assets surged 71.97% in 2023 and tumbled 41.53% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $166.8 million in 2022, then advanced by 10.11% to $183.7 million in 2023, then fell by 13.35% to $159.2 million in 2024, then plunged by 35.33% to $102.9 million in 2025, then jumped by 82.17% to $187.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $187.5 million in Q1 2026, $102.9 million in Q4 2025, and $107.0 million in Q3 2025.